CGA and pachyonychia congenita: This was confirmed in a recent study; CgA and neuron-specific enolase (NSE) levels, another neuroendocrine biomarker, were assessed in serum samples from 395 men at various stages of PC: 157 with hormone-naïve localised PC after radical prostatectomy and 238 with mCRPC (95 treated with first-line docetaxel and 143 treated with the first- or second-line abiraterone and/or enzalutamide) [13].